Publications by authors named "Jeff Keats"

Claim this Profile
T
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Sen Zhang, Rana Anjum, Rachel Squillace, Sara Nadworny, Tianjun Zhou, Jeff Keats

Clin Cancer Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.
Mathew Thomas, Wei-Sheng Huang, David Wen, Xiaotian Zhu, Yihan Wang, Jeff Keats

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Tianjun Zhou, Lois Commodore, Wei-Sheng Huang, Yihan Wang, Mathew Thomas, Jeff Keats

Chem Biol Drug Des· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
Wei-Sheng Huang, Chester A Metcalf, Raji Sundaramoorthi, Yihan Wang, Dong Zou, Jeff Keats

J Med Chem· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
9
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.
Wei-Sheng Huang, Xiaotian Zhu, Yihan Wang, Mohammad Azam, David Wen, Jeff Keats

J Med Chem· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity.
William C Shakespeare, Yihan Wang, Regine Bohacek, Terry Keenan, Raji Sundaramoorthi, Jeff Keats

Chem Biol Drug Des· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal structure of the T315I mutant of AbI kinase.
Tianjun Zhou, Lois Parillon, Feng Li, Yihan Wang, Jeff Keats

Chem Biol Drug Des· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
David Dalgarno, Thilo Stehle, Surinder Narula, Pierre Schelling, Marie Rose van Schravendijk, Jeff Keats

Chem Biol Drug Des· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis